Stock Events

Proteome Sciences 

$0.05
4
+$0+0% Monday 20:00

Statistics

Day High
0.08
Day Low
0.08
52W High
0.09
52W Low
0.03
Volume
3,000
Avg. Volume
65
Mkt Cap
16.12M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23AugExpected
Q2 2020
Q1 2021
Q2 2021
Q4 2021
Q2 2022
Q1 2024
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMSNF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bruker
BRKR
Mkt Cap8.99B
Bruker Corporation offers similar proteomics and analytical instrumentation solutions, directly competing in the proteomics research market.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific provides comprehensive analytical instruments and services for proteomics, making it a direct competitor in life sciences research.
Danaher
DHR
Mkt Cap180.39B
Danaher Corporation, through its subsidiaries like Sciex, competes in the mass spectrometry and proteomics analysis sector.
Waters
WAT
Mkt Cap17.96B
Waters Corporation specializes in analytical instruments for liquid chromatography and mass spectrometry, competing in the proteomics and analytical lab markets.
Agilent Technologies
A
Mkt Cap38.45B
Agilent Technologies offers a range of instruments and services for life sciences, including proteomics, making it a competitor in the analytical and life sciences industry.
Bio-Rad Laboratories
BIO
Mkt Cap8.45B
Bio-Rad Laboratories provides a variety of products for the life science research and clinical diagnostics markets, including proteomics, competing in the biotechnology tools sector.
Illumina
ILMN
Mkt Cap18.24B
Illumina, Inc. focuses on genomics but its advancements in sequencing technologies indirectly compete with proteomics by offering alternative approaches to biomarker discovery.
Guardant Health
GH
Mkt Cap3.76B
Guardant Health operates in the precision oncology field, and while primarily focused on genomic profiling, its move towards comprehensive cancer diagnostics competes with proteomics approaches in cancer research.
Qiagen NV
QGEN
Mkt Cap9.48B
Qiagen offers sample and assay technologies for molecular diagnostics and research, including proteomics. Their broad product range in genomics and molecular diagnostics places them as a competitor in the life sciences sector.

About

Pharmaceuticals: Major
Health Technology
Commercial Services
Miscellaneous Commercial Services
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Show more...
CEO
Ian Pike
Employees
35
Country
GB
ISIN
GB0003104196
WKN
000935051

Listings